Clinical trials: Respiratory Virus Infection
Coronavirus Disease 2019
Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
This is a clinical trial to evaluate the safety, PK, viral shedding and clinical effects of Pentarlandir™ UPPTA in patients with early COVID-19.
- Trial name
- NCT04911777
- Testing
- Pentarlandir™ UPPTA
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Malnutrition, Cancer
Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients
This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition…
- Conditions
- Malnutrition, Cancer, Inflammatory Bowel Diseases, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06055543
- Testing
- Fortimel
- Where
- 6 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Danone Specialized Nutrition
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Covid19
Clinical Study Spartan COVID-19 V2 System
This multicentre prospective study will enroll a sufficient number of patients to afford approximately 60 positives and > 40 negatives (as determined by the SOC - Comparator method) in the United States and/or Canada.
- Trial name
- NCT04575168
- Testing
- Spartan COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Spartan Bioscience Inc.
Influenza
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318149
- Testing
- Fluarix, Fluarix-AS25, Fluarix-AS50
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus Disease (COVID-19)
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery…
- Trial name
- NCT04575584
- Testing
- Molnupiravir
- Where
- 89 sites in United States, Brazil and 15 more
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
Primary objective: Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in…
- Trial name
- NCT00554333
- Testing
- Flu-ID 15μg, Inactivated adjuvanted Influenza Vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
COVID-19 Drug Treatment
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy.
- Trial name
- NCT04381884
- Testing
- IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
- Where
- 3 sites in Argentina
- Volunteers
- 45 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
SARS-CoV Infection
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.
- Trial name
- NCT04443868
- Testing
- Nitric Oxide-Releasing Drug
- Sponsor
- Sanotize Research and Development corp.
Influenza, Human
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
- Trial name
- NCT06573008
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Congenital Heart Disease
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
- Trial name
- NCT00538785
- Testing
- Motavizumab, Palivizumab
- Where
- 152 sites in United States, Austria and 15 more
- Volunteers
- 1,236 people
- Sponsor
- MedImmune LLC
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2010-2011 season.
- Trial name
- NCT01144299
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 6 sites in Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
This is a multi-center, comparative, two-arm, parallel-group, single-blind, phase III study to assess immunogenicity and safety of 4th LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) vaccination compared…
- Trial name
- NCT01251133
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- LG Life Sciences
Influenza
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one administration of OVX836 influenza vaccine at different dose levels (180µg, 300μg and 480μg) in order to assess the dose response of…
- Trial name
- NCT05060887
- Testing
- OVX836-003, Saline solution
- Where
- Belgium
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Osivax
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.